vTv Therapeutics Announces 2024 Fourth Quarter and Full Year Financial Results and Provides Corporate Update

Core Insights - vTv Therapeutics has lifted the clinical hold on its cadisegliatin program for type 1 diabetes, allowing the Phase 3 CATT1 trial to resume in Q2 2025 [1][5] - The company has appointed Martin Lafontaine as Chief Commercial Officer to enhance its commercial strategy for cadisegliatin [2][5] Recent Developments - The FDA lifted the clinical hold on March 14, 2025, enabling the company to amend the CATT1 trial protocol, reducing its duration from 12 months to 6 months without affecting key endpoints [5] - Martin Lafontaine brings over 27 years of experience in the pharmaceutical and medical device industry, particularly in diabetes, which is expected to strengthen the company's market position [2][5] Financial Results - As of December 31, 2024, vTv Therapeutics reported a cash position of $36.7 million, a significant increase from$9.4 million a year earlier, primarily due to private placement financing [5] - Research and Development (R&D) expenses for Q4 2024 were $2.2 million, slightly up from$2.1 million in Q4 2023, while full-year R&D expenses decreased to $11.5 million from$13.6 million in 2023 [6][10] - General and Administrative (G&A) expenses for Q4 2024 were $2.7 million, compared to$2.6 million in Q4 2023, with full-year G&A expenses increasing to $13.7 million from$11.9 million in 2023 [6][10] Operational Metrics - The net loss attributable to vTv shareholders for Q4 2024 was $3.6 million, or$0.55 per share, compared to a net loss of $3.5 million, or$1.67 per share, in Q4 2023 [10][14] - For the full year 2024, the net loss attributable to vTv shareholders was $18.5 million, or$3.20 per share, down from a net loss of $20.3 million, or$9.71 per share, in 2023 [10][14]